Title

Earning Preview: Boston Scientific this quarter’s revenue is expected to increase by 19.32%, and institutional views are bullish

Abstract

Boston Scientific will release its fourth-quarter 2025 results on February 04, 2026 Pre-Market, with current consensus pointing to sustained double-digit revenue growth and higher adjusted EPS as analysts emphasize execution consistency and segment-level momentum across Cardiovascular and MedSurg.

Market Forecast

Consensus for Boston Scientific’s current quarter points to total revenue of USD 5.28 billion, up 19.32% year over year, and adjusted EPS of USD 0.78, up 18.78% year over year; EBIT is forecast at USD 1.45 billion, implying 20.96% year-over-year growth. Gross profit margin and net profit margin are not provided in current-quarter consensus forecasts; however, strength in core franchises and product adoption underpin expectations for continued operating leverage and EPS expansion in the period.

The main business remains anchored by the Cardiovascular and MedSurg portfolios, with ongoing momentum in atrial fibrillation therapies, electrophysiology, and procedural tools supporting double-digit organic growth. The most promising segment is Cardiovascular, which delivered USD 3.34 billion last quarter, and the company’s total revenue is expected to grow 19.32% year over year in the current quarter as adoption trends continue and new indications broaden the addressable base.

Last Quarter Review

Boston Scientific reported last quarter revenue of USD 5.07 billion, a gross profit margin of 69.69%, GAAP net profit attributable to the parent company of USD 755.00 million, a net profit margin of 14.91%, and adjusted EPS of USD 0.75, up 19.05% year over year.

A key highlight was a clean beat against street expectations: revenue exceeded consensus by USD 0.10 billion, adjusted EPS topped expectations by USD 0.04, and EBIT reached USD 1.42 billion; on a sequential basis, GAAP net profit declined 5.27% quarter over quarter, reflecting normal mix and timing effects. Main business performance was broad-based, with Cardiovascular contributing USD 3.34 billion and MedSurg contributing USD 1.72 billion; total revenue grew 20.34% year over year on continued strength across procedure-driven categories.

Current Quarter Outlook

Cardiovascular Segment Outlook

Cardiovascular anchored last quarter’s performance with USD 3.34 billion in revenue, and remains the core engine for this quarter’s projection as consensus expects total company revenue to rise 19.32% year over year. Adoption in left atrial appendage closure, alongside continued demand in electrophysiology and interventional cardiology, is likely to sustain positive mix and support margin resilience. With adjusted EPS forecast at USD 0.78, investors will be watching the interplay between volume, price discipline, and manufacturing efficiency to gauge durability of operating leverage.

Analyst commentary across multiple institutions consistently emphasizes WATCHMAN growth and execution reliability, which align with the current-quarter expectations for double-digit revenue expansion. This segment’s contribution to gross profit continues to be meaningful given last quarter’s 69.69% gross margin, suggesting that even moderate volume outperformance can translate into incremental EPS gain within the broader USD 1.45 billion EBIT framework. Segment momentum, if confirmed by updated procedure volumes and geographic breadth, would validate the current revenue cadence and potentially set the stage for favorable full-year growth algorithms.

From a cadence standpoint, the fourth quarter often encompasses balanced procedure activity and inventory management, making quarter-on-quarter comparisons sensitive to timing. Management’s full-year framework of USD 20.00 billion for 2025, referenced earlier in the season, implies an average second-half revenue run-rate near the USD 5.10 billion mark, which provides context for this quarter’s USD 5.28 billion consensus. Execution against that framework will likely hinge on stable capacity utilization, continued training and education programs, and a measured rollout of incremental indications that can expand patient eligibility without materially disrupting operational throughput.

MedSurg Segment Outlook

MedSurg contributed USD 1.72 billion last quarter and is positioned to deliver steady growth in the current quarter as utilization of endoscopy and urology tools remains stable across major markets. Clinical updates in urology and stone management — including ongoing evaluation of laser-based therapies in kidney stone treatment contexts — are potentially supportive for MedSurg sales trajectories, reinforcing its role as a dependable contributor. While MedSurg’s revenue base is smaller than Cardiovascular, its recurring-procedure profile can provide resilience and dampen volatility in quarters where capital placement mix or high-value device timing affects Cardiovascular.

For this quarter, visibility into MedSurg demand trends will center on procedure volumes, refresh cycles for visualization platforms, and utilization of stone and laser therapies. The segment’s product diversity and institutional customer relationships typically support consistent ordering patterns, which are conducive to incremental gross margin contribution and stable cash conversion. If procedure volumes in endoscopy and urology track well relative to historical seasonal norms, MedSurg may offer a modest upside offset to any Cardiovascular timing shifts, helping keep the total revenue line near the USD 5.28 billion expectation.

Importantly, MedSurg’s steady-state growth is accretive to adjusted EPS and EBIT when cost discipline aligns with volume flow-through. Even modest pricing and mix tailwinds in consumables and accessories can compound into meaningful quarterly leverage given last quarter’s 69.69% gross margin backdrop. This dynamic complements the broader company narrative, where MedSurg’s consistent performance stabilizes the aggregate operating profile across diverse procedural settings.

Stock Price Drivers This Quarter

Stock performance around the print will likely be driven by whether Boston Scientific can exceed the USD 5.28 billion revenue and USD 0.78 adjusted EPS benchmarks while showcasing stable margins and confirming the sustainability of double-digit growth. Investors will scrutinize updated gross margin color relative to last quarter’s 69.69% and net profit margin updates relative to the 14.91% baseline to assess the depth of operating leverage. Qualitative commentary around demand trends in atrial fibrillation therapies, electrophysiology, and procedural tools will be pivotal in shaping near-term valuation sentiment.

Management’s updated perspective on the full-year sales framework of USD 20.00 billion for 2025 will serve as a useful reference point for the pacing of this quarter’s results and implied exit velocity into 2026. Affirmation of organic growth durability, coupled with operational efficiency commentary, may be valued as much as the absolute magnitude of any beat. Conversely, if quarter-on-quarter fluctuations in certain product categories temper margin trajectory, investors will weigh the confidence of guidance and the cadence of pipeline catalysts through the first half of 2026.

Analysts have highlighted diversified growth engines and strong execution as key themes, which suggests the market is prepared to reward a clean, in-line-to-better outcome with constructive guidance. Evidence of continued share gains in core therapy areas, strong utilization data, and disciplined expense management could reinforce the EPS runway beyond this quarter. On balance, the setup frames the debate around the degree of outperformance relative to consensus and the clarity provided on full-year growth algorithms and capital allocation priorities.

Analyst Opinions

Across collected views within the last six months, the ratio of bullish to bearish opinions on Boston Scientific is overwhelmingly skewed toward bullish, with a broad slate of Buy ratings and positive previews forming the clear majority. Barclays reiterated a Buy rating with a USD 136.00 price target, underscoring the continuation of strong revenue growth engines and consistent execution. Citi maintained a Buy stance with emphasis on diversified growth pathways and resilient performance across core franchises, while Bernstein reaffirmed its Buy rating with a USD 130.00 target, citing operational consistency and favorable trajectory in high-growth therapies.

BTIG kept its Buy rating with a USD 132.00 target, pointing to stability in MedSurg and ongoing momentum in Cardiovascular, and Needham reiterated a Buy view highlighting last quarter’s strong performance and growth in WATCHMAN adoption. TD Cowen maintained a Buy rating with a USD 115.00 target, emphasizing revenue scalability and operating leverage, and Evercore ISI continued its bullish stance, aligning with the consensus framework for double-digit expansion. Jefferies reiterated a Buy rating with a USD 132.00 target, signaling confidence in Boston Scientific’s ability to meet or exceed current-quarter expectations; Bank of America’s commentary similarly emphasized strong performance and a promising outlook.

The majority view focuses on three consistent themes: sustained double-digit revenue expansion, disciplined margin management that underpins adjusted EPS growth, and product-driven momentum across key therapy areas. Analysts coalesce around the notion that current-quarter projections — USD 5.28 billion in revenue and USD 0.78 in adjusted EPS — are attainable within the company’s execution track record, with potential for modest upside if mix benefits and volume trends play through. In their analysis, the breadth of Buy ratings functions as a validation of the growth algorithm, suggesting that clear communication on pacing, margins, and segment-level demand should be sufficient to keep institutional sentiment constructive through the quarter’s print and beyond.

In sum, institutional views are predominantly bullish, anchored by confidence in Boston Scientific’s ability to deliver against consensus and to reinforce visibility into continued earnings expansion. While the exact magnitude of upside versus expectations will depend on volume mix and margin commentary, the weight of analyst opinion indicates that a clean set of results, coupled with consistent guidance language, would support the current valuation narrative. With earnings scheduled on February 04, 2026 Pre-Market, the prevailing stance anticipates that operational execution and segment momentum will remain the central validation points for the quarter.